“Busan is a good city to live in, but a difficult one for startups.” “However, the growth potential of Busan’s biohealth industry is significant.”
Since COVID-19, the global market size of the biohealth industry has rapidly expanded. In line with this trend, a networking platform was launched in Busan, allowing biohealth startups to share information and explore investment opportunities.
Led by Busan City and the Busan Medical Industry Council, the “Build-up Biohealth Busan Forum,” launched last year, hosted the “Busan Biohealth Startup Night” on the evening of the 29th at the Lotte Hotel Busan. The event gathered more than 60 attendees, including forum chairman Kim Hyung-hoe (Director of Busan National University Medical Research Institute), representatives from the city, companies, hospitals, and related organizations.
Presenters at the forum discussed the current status and outlook of the domestic biohealth market, successful startup cases, and investment trends, receiving positive responses from participants.
Sung Hee-yeop, head of the Busan Startup Agency Establishment Task Force, emphasized the need for policy shifts in Busan’s startup ecosystem. He stated, “The reason growing companies leave Busan is due to difficulties in securing investment and talent. The concentration of policies in the capital region and Busan’s conservative culture also push companies away.” He suggested increasing public investment funds and unifying fragmented startup policies across departments.
Choi Woo-sik, CEO of Deepnoid, an AI healthcare platform company, predicted, “The convergence of AI, Web3, and healthcare will open huge opportunities for startups.”
Kim Sung-geun, Planning and Coordination Director of Pusan National University Holdings, explained their investment and commercialization achievements. He said, “We operate ‘P&U Avec,’ the nation’s first startup support platform without government subsidies, actively supporting early-stage startups.”
Lee Joo-hwan, Senior Investment Officer at Mirae Asset Venture Investment, noted, “Over the past 10 years, investments in Korea’s biohealth sector have grown more than 14-fold. We need to increase opportunities for local companies to meet capital-region investors, such as by holding demo days via Zoom.”
Local universities also showcased their technologies. Highceltech CEO and Pusan National University professor Kim Jae-ho introduced a “metastatic cancer targeted therapy,” while T-Cure CEO and Pukyong National University professor Kang Hyun-wook presented a laser treatment technology for tubular diseases.
Reported by Kim Dong-joo Read the original article
“Busan is a good city to live in, but a difficult one for startups.” “However, the growth potential of Busan’s biohealth industry is significant.”
Since COVID-19, the global market size of the biohealth industry has rapidly expanded. In line with this trend, a networking platform was launched in Busan, allowing biohealth startups to share information and explore investment opportunities.
Led by Busan City and the Busan Medical Industry Council, the “Build-up Biohealth Busan Forum,” launched last year, hosted the “Busan Biohealth Startup Night” on the evening of the 29th at the Lotte Hotel Busan. The event gathered more than 60 attendees, including forum chairman Kim Hyung-hoe (Director of Busan National University Medical Research Institute), representatives from the city, companies, hospitals, and related organizations.
Presenters at the forum discussed the current status and outlook of the domestic biohealth market, successful startup cases, and investment trends, receiving positive responses from participants.
Sung Hee-yeop, head of the Busan Startup Agency Establishment Task Force, emphasized the need for policy shifts in Busan’s startup ecosystem. He stated, “The reason growing companies leave Busan is due to difficulties in securing investment and talent. The concentration of policies in the capital region and Busan’s conservative culture also push companies away.” He suggested increasing public investment funds and unifying fragmented startup policies across departments.
Choi Woo-sik, CEO of Deepnoid, an AI healthcare platform company, predicted, “The convergence of AI, Web3, and healthcare will open huge opportunities for startups.”
Kim Sung-geun, Planning and Coordination Director of Pusan National University Holdings, explained their investment and commercialization achievements. He said, “We operate ‘P&U Avec,’ the nation’s first startup support platform without government subsidies, actively supporting early-stage startups.”
Lee Joo-hwan, Senior Investment Officer at Mirae Asset Venture Investment, noted, “Over the past 10 years, investments in Korea’s biohealth sector have grown more than 14-fold. We need to increase opportunities for local companies to meet capital-region investors, such as by holding demo days via Zoom.”
Local universities also showcased their technologies. Highceltech CEO and Pusan National University professor Kim Jae-ho introduced a “metastatic cancer targeted therapy,” while T-Cure CEO and Pukyong National University professor Kang Hyun-wook presented a laser treatment technology for tubular diseases.
Reported by Kim Dong-joo Read the original article